Authors

Latest:

Leveraging Endoscopic Ultrasound in Pancreatic Cancer: Looking to the Future

In this final episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, reiterate that the role of endoscopic therapies in pancreatic cancer continues to evolve.

Aristotelis Bamias, MD

Latest:

Dr. Bamias on Final Analysis of Atezolizumab Monotherapy in the IMvigor130 Trial in mUC

Aristotelis Bamias, MD, discusses key efficacy data from a final analysis of the phase 3 IMvigor130 trial in metastatic urothelial carcinoma.

Angeles Alvarez Secord, MD, MHSc

Latest:

Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents

Panelists discuss recent data on emerging antibody-drug conjugates in advanced and recurrent endometrial cancer, including anti-TROP2 agents like sacituzumab govitecan from the TROPiCS-03 trial, datopotamab deruxtecan from TROPION-PanTumor03, and sacituzumab tirumotecan, as well as anti–folate receptor agents like luveltamab tazevibulin and rinatabart sesutecan, while offering future perspectives and closing thoughts on the evolving role of these agents in the treatment landscape for endometrial cancer.

Jennifer Crombie, MD

Latest:

FDA Approval Insights: Epcoritamab in Relapsed/Refractory Follicular Lymphoma

Jennifer Crombie, MD, shares insights about the FDA's approval of epcoritamab for patients with relapsed/refractory follicular lymphoma.

Samuel Kareff, MD, MPH

Latest:

The Importance of Hematology/Medical Oncology Fellowship

Samuel A. Kareff, MD, MPH, shares his reflections on the benefits, challenges, and critical elements of effective mentorship in hematology/oncology.

Barbara Melosky, MD, FRCPC

Latest:

Dr. Melosky on the Use of Lurbinectedin in SCLC

Barbara Melosky, MD, FRCPC, discusses the use of lurbinectedin in small cell lung cancer.

Cassandra A. Hathaway, MD

Latest:

Dr Hathaway on the Investigation of Distress on the TME in Ovarian Cancer

Cassandra A. Hathaway, MD, discusses the rationale for investigating the association between distress, such as depression, and the tumor immune microenvironment in patients with ovarian cancer.

Michael Chuong, MD, FACRO

Latest:

Dr Chuong on the Patterns of Guided Radiation Therapy in Pancreatic Cancer

Michael Chuong, MD, FACRO, discusses patterns of locoregional recurrence following guided radiation therapy in pancreatic cancer.

Callie Coombs, MD

Latest:

Dr Coombs on Notable BTK Inhibitor Combination Studies in CLL

Callie Coombs, MD, discusses the investigation of notable BTK inhibitor combination trials in patients with chronic lymphocytic leukemia.

Andrew S. Brohl, MD

Latest:

Dr Brohl on the Safety and Efficacy of IFx-Hu2.0 in MCC and CSCC

Andrew S. Brohl, MD, discusses the safety and immunologic responses with intratumoral administration of Idx-Hu2.0 in patients with advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Konstantinos Arnaoutakis, MD

Latest:

Dr. Arnaoutakis on the ADAURA Trial Examining Osimertinib in EGFR-Mutant Lung Cancer

Konstantinos Arnaoutakis, MD, discusses the phase 3 ADAURA trial examining osimertinib in the adjuvant treatment of patients with EGFR-mutant lung cancer.

Lewis Au, MBBS, BMedSci, FRACP

Latest:

Dr. Au on the Results of a Subgroup Analysis Evaluating Antibody Response to COVID-19 in Cancer

Lewis Au, MBBS, BMedSci, FRACP, discusses the results of a subgroup analysis evaluating antibody responses to COVID-19 in patients with cancer.

Devika Das, MD, MSHQS

Latest:

Dr Das on the Use of Neoadjuvant and Adjuvant Chemoimmunotherapy Regimens in NSCLC

Devika Das, MD, MSHQS, discusses the use of neoadjuvant and adjuvant chemoimmunotherapy for patients with resectable non–small cell lung cancer, and emphasizes the importance of multidisciplinary collaboration when incorporating these regimens into treatment approaches.

John M. Burke, MD, Rocky Mountain Cancer Centers

Latest:

Dr Burke on Challenges Associated With Initiating Venetoclax in Patients With CLL

John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.

Arnulf Stenzl, MD

Latest:

Dr. Stenzl on Future Research With Enzalutamide in Prostate Cancer

Arnulf Stenzl, MD, discusses future research efforts with enzalutamide in prostate cancer.

Michael Smylie, MBBS, FRCPC

Latest:

Considerations for Taking Oncology Care "to the Ends of the Earth": With D. Ross Camidge, MD, PhD; and Michael Smylie, MBBS, FRCPC

Drs Camidge and Smylie discussed Dr Smylie’s experience treating patients who live in the Northwest Territories of Canada.

Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medicine

Latest:

Dr. Tagawa on the Evolution of ADCs in mCRPC

Scott Tagawa, MD, MS, FACP, discusses the evolution of antibody-drug conjugates in metastatic castration-resistant prostate cancer, as well as potential future targets for ADC development in this space.

Bruna Pellini, MD

Latest:

Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer

Dr. Bruna Pellini presents key data comparing real-world outcomes of atezolizumab versus durvalumab in extensive-stage small cell lung cancer (ES-SCLC), demonstrating a significant overall survival advantage and lower immune-related adverse events with durvalumab, while progression-free survival remained comparable between the two treatments.

Md Kamrul Hasan, PhD

Latest:

Dr Hasan on the Preclinical Efficacy of ROR1-Specific CAR T-Cells in CLL

Md Kamrul Hasan, PhD, discusses the preclinical efficacy and safety of ROR1-specific CAR T-cells in a preclinical mouse model of chronic lymphocytic leukemia.

Arutha Kulasinghe, PhD

Latest:

Dr Kulasinghe on a Study Profiling the NSCLC Tumor Microenvironment

Arutha Kulasinghe, PhD, discusses findings from a study profiling the tumor microenvironment of non–small cell lung cancer, as well as future directions planned with this research and the implications of these findings.